Cosmo Pharmaceuticals N.V. (FRA:C43)

Cosmo Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	50.75	44.3	50.28	185.83	198.56	185.94
Short-Term Investments	1.18	17.99	-	52.7	-	-
Trading Asset Securities	74.69	80.68	-	2.43	23.65	26.92
Cash & Short-Term Investments	126.63	142.96	50.28	240.95	222.21	212.85
Cash Growth	-5.09%	184.36%	-79.14%	8.44%	4.40%	-20.64%
Accounts Receivable	21.62	18.94	28.45	38.61	24.45	26.99
Other Receivables	26.61	1.68	2.22	2.69	3.23	1.15
Receivables	48.22	20.62	30.67	41.3	27.68	28.14
Inventory	12.38	13.51	14.2	11.5	13.12	5.71
Prepaid Expenses	-	15.2	3.32	3.06	1.96	2.69
Other Current Assets	-	9.97	3.76	9.28	10.88	3.48
Total Current Assets	187.23	202.26	102.23	306.1	275.85	252.87
Property, Plant & Equipment	29.77	29.09	28.59	30.28	30.48	29.3
Long-Term Investments	11.25	31.84	3.29	8.27	49.08	250.61
Goodwill	24.01	24.01	24.01	24.01	24.01	1.44
Other Intangible Assets	329.13	161.66	116.15	360.89	369.31	3.24
Long-Term Deferred Tax Assets	19.68	18.72	19.83	14.68	18.64	8.2
Long-Term Deferred Charges	-	170.27	222.21	5.5	3.42	23.4
Other Long-Term Assets	9.27	8.94	9.75	9.87	9.78	1.81
Total Assets	610.33	646.77	526.05	759.59	805.56	596.16
Accounts Payable	11.03	9.1	8.78	7.59	8.3	5.95
Accrued Expenses	2	3.42	6.02	5.9	5.25	2.98
Current Portion of Long-Term Debt	0.14	0.14	0.14	171.07	0.13	0.13
Current Portion of Leases	0.62	0.68	0.76	0.76	0.76	2.81
Current Income Taxes Payable	20.12	19.95	2.17	2.29	3.25	2.46
Current Unearned Revenue	-	-	-	-	-	0.14
Other Current Liabilities	14.82	14.98	7.25	7.35	3.55	7.32
Total Current Liabilities	48.72	48.27	25.12	194.95	21.24	21.79
Long-Term Debt	0.28	0.28	0.42	0.56	167.15	163.02
Long-Term Leases	1.66	1.1	0.52	1.21	1.88	2.19
Long-Term Deferred Tax Liabilities	91.58	90.81	92.61	97.1	99.75	6.27
Other Long-Term Liabilities	0.57	0.57	3.2	1.58	2.39	2.39
Total Liabilities	143.35	141.68	122.42	295.8	292.88	196.04
Common Stock	4.56	4.56	4.56	4.56	4.56	3.91
Additional Paid-In Capital	243.57	243.57	243.57	243.57	243.57	84.45
Retained Earnings	363.35	373.6	271.18	310.09	341.16	265.35
Treasury Stock	-108.79	-104.11	-101.31	-89.8	-65.56	-49.4
Comprehensive Income & Other	-42.44	-19.28	-21.18	-11.49	-18.45	95.82
Total Common Equity	460.24	498.33	396.82	456.93	505.28	400.13
Minority Interest	6.74	6.76	6.81	6.86	7.4	-
Shareholders' Equity	466.98	505.09	403.62	463.79	512.68	400.13
Total Liabilities & Equity	610.33	646.77	526.05	759.59	805.56	596.16
Total Debt	2.7	2.2	1.84	173.6	169.92	168.14
Net Cash (Debt)	123.93	140.76	48.44	67.36	52.29	44.71
Net Cash Growth	-6.09%	190.61%	-28.09%	28.81%	16.96%	-56.75%
Net Cash Per Share	7.58	8.57	3.01	4.10	3.09	3.09
Filing Date Shares Outstanding	15.94	16.02	16.05	16.26	16.71	14.43
Total Common Shares Outstanding	15.94	16.02	16.05	16.26	16.71	14.43
Working Capital	138.51	153.99	77.11	111.15	254.61	231.08
Book Value Per Share	28.88	31.12	24.72	28.10	30.24	27.72
Tangible Book Value	107.11	312.67	256.66	72.04	111.96	395.44
Tangible Book Value Per Share	6.72	19.52	15.99	4.43	6.70	27.40
Land	-	24.64	25.01	24.97	24.02	22.79
Machinery	-	50.74	47.95	45.14	40.16	37.99
Construction In Progress	-	1.41	-	-	1.67	0.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.